Institution:
Stony Brook University School of MedicineResearchers:
Lorne Golub, DMD, MSc, of the Department of Oral Biology and Pathology at Stony Brook Medicine
Impact:
Rosacea affects an estimated 16 million Americans. Dr. Golub was the principal investigator of the research leading to the development of Oracea. The drug delivers a dose of doxycycline that is not strong enough to kill bacteria, but that will reduce lesions and inflammation.
Timeline:
FDA approval in 2006